



PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

April 27, 2026

RNS Number : 9985B
PureTech Health PLC
27 April 2026

27 April 2026

PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

[PureTech Health plc](#) (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mates to its Board of Directors.

Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately \$14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major strategic transaction.

The full text of the announcement from Seaport is as follows:

Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

Dr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a \$14.6 billion acquisition by Johnson & Johnson

[Seaport Therapeutics](#) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the appointment of Dr. Sharon Mates to its Board of Directors.

Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately \$14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major strategic transaction.

"Sharon is an exceptional biotech entrepreneur and leader whom I have admired for years. We are delighted to welcome her to our Board," said Daphne Zohar, Founder and Chief Executive Officer of Seaport Therapeutics. "Her significant experience, intellectual curiosity, deep industry relationships, and genuine appreciation for our patient-centered approach will meaningfully support Seaport's mission to develop life-changing treatments for patients with depression, anxiety, and other neuropsychiatric disorders."

"I have followed Seaport's programs with great interest and believe Seaport is positioned to have a significant impact in neuropsychiatry," said Dr. Sharon Mates. "I look forward to working closely with Daphne as I have long respected the vision and leadership she brings as a fellow founder and CEO whose work has impacted patients. I'm also excited about collaborating with long-time colleagues from the neuropsychiatry field including Steve Paul, Tony Loebel, and other members of the team and Board to help guide Seaport's continued growth and advance its mission to develop life-changing treatments for patients."

Under Dr. Mates' leadership, Intra-Cellular Therapies developed medicines for mental health disorders including bipolar disorder, depression, and schizophrenia, and received U.S. Food and Drug Administration (FDA) approval for its novel antipsychotic CAPLYTA[®], which generated greater than \$1.5 billion in sales prior to the company's acquisition by J&J, and continued its commercial growth thereafter driven by expanded market reach and additional FDA approvals.

"Sharon brings scientific and strategic depth in neuropsychiatry, including completing the journey from complex neuroscience drug discovery to real-world medicines," said Steven Paul, M.D., Co-Founder and Board Chair of Seaport Therapeutics. "Having witnessed Sharon's impact on CNS drug development over many decades, it is a privilege to serve alongside her on the Board as we extend that impact through our work at Seaport developing important new medicines for patients with debilitating neuropsychiatric disorders."

Dr. Mates brings board-level and governance experience, having served on biotech and biopharmaceutical company boards, as well as several not-for-profit boards. She currently serves on the boards of MedinCell (Euronext: MEDCL) and Benitec (Nasdaq: BNTC). Dr. Mates is presently forming a new company in the areas of inflammation, metabolism, and other indications. Earlier in her career, she was a research analyst, investment banker, and an advisor to the life sciences industry. Dr. Mates received a B.S. from Ohio State University, a Ph.D. from the University of Washington and completed her postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School.

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph[™] platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit www.seaporttx.com.

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and

de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

For more information, visit www.puretechhealth.com or connect with us on [LinkedIn](#) and X (formerly Twitter) [@puretechh](#).

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to those related to Seaport's development plans for its pipeline of neuropsychiatric therapeutics based on the Glyph™ Platform, the potential of the Glyph platform, the broader applicability of the platform, potential benefits to patients, and Seaport's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com

US Media

Justin Chen

jchen@tenbridgecommunications.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEAELXASKKEEA